The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis

Autoimmune Pulmonary Alveolar Proteinosis Clinical Trial

— LongPAP  

Official title:

The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03531996
• Other study ID #: 2017-7514
• Secondary ID: U54HL127672
• Status: Completed
• Start date: April 19, 2018
• Est. completion date: September 16, 2020

Study information

• Verified date: June 2021
• Source: Children's Hospital Medical Center, Cincinnati
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The major goal of this study is to conduct a prospective, longitudinal study of autoimmune PAP to examine outcome measures for disease severity of potential use in clinical practice and/or clinical research studies. These results will impact the field by: 1) improving an understanding of the clinical course of autoimmune PAP, 2) providing information on various clinical outcome and quality of life outcome measures to guide patients and physicians in making treatment choices, and 3) facilitate the development of pharmaco-therapeutics for autoimmune PAP and 4) better informing PAP researchers.

Description:

PAP is a rare syndrome of surfactant accumulation and resulting hypoxemic respiratory failure that occurs in a number of diseases classified pathogenically into three groups: primary PAP (caused by disruption of GM-CSF signaling - autoimmune PAP, hereditary PAP), secondary PAP (caused by reduction in alveolar macrophage numbers and/or functions), and surfactant dysfunction-related PAP (caused by mutations in genes required for normal surfactant production). In current clinical practice, PAP is diagnosed based on a lung biopsy; an approach that is not able to identify the PAP-causing disease in anyone. Current therapy involves the physical removal of surfactant by a procedure in which the lungs are repeatedly filled with saline and emptied - whole lung lavage, which is invasive, inefficient, and not widely available, especially for children. Importantly, research advances have elucidated the pathogenesis of diseases causing PAP in most patients and have identified new diagnostic and therapeutic approaches. Simple blood-based research tests can now identify the PAP-causing disease in about 95% of patients. Further, several promising potential disease-specific therapies are currently in development. The long-term goals of the Rare Lung Diseases Consortium include improving the diagnosis and therapy of people with PAP. A major goal of this protocol is to conduct a prospective, longitudinal study of autoimmune PAP to examine outcome measures for disease severity for potential use in clinical practice and/or clinical research studies. The investigator's central hypothesis is that a prospective, longitudinal study of autoimmune PAP patients will facilitate the identification of useful outcome measures for use in clinical practice and/or clinical research studies. The specific objectives of the study are to: 1) evaluate blood-based biomarkers of PAP lung disease over time in autoimmune PAP patients, 2) evaluate the natural history/clinical course of autoimmune PAP over time, 3) evaluate quality of life measures over time in autoimmune PAP patients, 4) evaluate physiologic measures of disease over time in autoimmune PAP patients, and 5) evaluate radiologic measures of lung disease progression over time in autoimmune PAP patients. The study design will be observational and will involve recruitment, screening, and enrollment of eligible participants and annual collection of clinical data. The experimental approach will be to assess the rate of change in GM-CSF signaling assay parameters from baseline to 24 months. GM-CSF signaling assay parameters include GM-CSF autoantibody (GMAb) level, pSTAT5-Max, STAT5-phosphorylation index (STAT5-PI), GM-CSF signaling index (GM-SI), and GM-CSF EC50. The study will also assess the progression of autoimmune PAP, including but not limited to use of treatment options, the number and types of infections and other inter-current medical issues with quality of life measures, exercise tolerance, and radiologic imaging. Experimental outcomes will evaluate SP-D, cholestenoic acid, and lipid levels. Anticipated results will establish a natural history/clinical course of autoimmune PAP to better serve patients and providers, to better inform PAP researchers, and validate outcome measures and biomarkers for use in future clinical studies of PAP. These results will impact the field by: 1) improving an understanding of the clinical course of autoimmune PAP, 2) providing information on various clinical outcome and quality of life outcome measures to guide patients and physicians in making treatment choices, and 3) facilitate the development of pharmacotherapeutics for autoimmune PAP and 4) better informing PAP researchers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: September 16, 2020
• Est. primary completion date: September 16, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Written informed consent must be provided by:

• Participant if at least 18 years old -OR-

• Parent/legal guardian if participant is less than 18 years old -AND-

• Participant provides assent when appropriate

• History of diagnosis of autoimmune as indicated by a:

• History of chest CT or x-ray findings compatible with PAP -AND-

• History of a Positive (Abnormal) serum GMAb test

Exclusion Criteria:

• Individuals who have a serious medical illness that, in the opinion of the investigator, is likely to interfere with completion of the study will be excluded.

Related Conditions & MeSH terms

• Autoimmune Diseases
• Autoimmune Pulmonary Alveolar Proteinosis
• Pulmonary Alveolar Proteinosis

Locations

Country	Name	City	State
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio

Sponsors (3)

Lead Sponsor	Collaborator
Children's Hospital Medical Center, Cincinnati	National Heart, Lung, and Blood Institute (NHLBI), Rare Diseases Clinical Research Network

Country where clinical trial is conducted

United States, 

References & Publications (3)

Carey B, Trapnell BC. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol. 2010 May;135(2):223-35. doi: 10.1016/j.clim.2010.02.017. Epub 2010 Mar 25. Review. — View Citation

Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003 Dec 25;349(26):2527-39. Review. — View Citation

Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, Sakagami T, Koch DE, Stevens C, Inoue Y, Yamada Y, Trapnell BC. Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods. 2014 Jan 15;402(1-2):57-70. doi: 10.1016/j.jim.2013.11.011. Epub 2013 Nov 23. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Longitudinal evaluation of GM-CSF autoantibody levels	Change in GM-CSF autoantibody levels in autoimmune PAP patients over time	Baseline, 1 year, and 2 years
Primary	Longitudinal evaluation of the maximal phospho-STAT5 level after GM-CSF stimulation	Change in phospho-STAT5 levels in autoimmune PAP patients over time	Baseline, 1 year, and 2 years
Primary	Longitudinal evaluation of the STAT5 Phosphorylation Index	Change in the STAT5 phosphorylation index in autoimmune PAP patients over time	Baseline, 1 year, and 2 years
Primary	Longitudinal evaluation of the GM-CSF Signaling Index	Change in GM-CSF signaling index in autoimmune PAP patients over time	Baseline, 1 year, and 2 years
Primary	Longitudinal evaluation of the dose GM-CSF to stimulation 1/2 maximal STAT5 phosphorylation (EC50)	Change in GM-CSF EC50 level in autoimmune PAP patients over time	Baseline, 1 year, and 2 years
Secondary	Frequency of therapeutic intervention	Change over time in the patient's history of a need for therapeutic intervention	Baseline, 1 year, and 2 years
Secondary	Concurrent infections	Change over time in the patient's history of concurrent infections	Baseline, 1 year, and 2 years
Secondary	Blood SP-D	Change over time in serum SP-D levels	Baseline, 1 year, and 2 years
Secondary	Blood cholestenoic acid	Change over time in cholestenoic acid levels	Baseline, 1 year, and 2 years
Secondary	Blood lipid levels	Change over time in blood lipid levels	Baseline, 1 year, and 2 years
Secondary	Quality of Life measured by St. George Respiratory Questionnaire	Change over time in the overall health, daily life, and perceived well-being in patients with obstructive airways disease. The questionnaire is divided into two parts: Part 1: Symptoms component (frequency & severity) with a 1, 3 or 12-month recall (best performance with 3- and 12-month recall); Part 2: Activities that cause or are limited by breathlessness; Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall.	Baseline, 1 year, and 2 years
Secondary	Shortness of breath measured by San Diego Dyspnea Score	Change over time in the severity of shortness of breath on a 6-point scale (0 = Not at all, 5 = Maximally or unable to do because of breathlessness) during 21 activities of daily living associated with varying levels of exertion. Three additional questions ask about fear of harm from overexertion, limitations, and fear caused by shortness of breath, for a total of 24 items. If patients do not routinely perform an activity, they are asked to estimate their anticipated shortness of breath. A total sum score ranges from 0 to 120.	Baseline, 1 year, and 2 years
Secondary	Minimum SpO2 during a standardized exercise protocol	Change over time in the minimum SpO2 during exercise on a scale of 0 to 100. The study will be stopped if the Sp02 reaches 88%.	Baseline, 1 year, and 2 years
Secondary	Time during standardized exercise protocol required for SpO2 to fall below 88%	Change over time in the time for the SpO2 to fall below 88% during the standardized exercise protocol while patients step onto and off of a step for 5 minutes.	Baseline, 1 year, and 2 years